Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheumatologist Lars Klareskog, MD, PhD, In the Spotlight

Gretchen Henkel  |  Issue: December 2014  |  December 1, 2014

Dr. Klareskog is both “a good mentor and a good scientist,” remarks Alvin F. Wells, MD, PhD, director of the Rheumatology and Immunotherapy Center in Franklin, Wis., and a leading U.S. clinical trials researcher. Dr. Wells was Dr. Klareskog’s first postdoctoral fellow while the latter was teaching at Uppsala University in 1988. Since that time, the two have published nine papers together as their research interests have overlapped. “He is inclusive and lets others take a leadership role, gives credit where credit is due and is one of our outstanding fellow leaders,” Dr. Wells says.

Equally important has been the opportunity to contribute to collaborations using the opportunities that have been provided by EU funding of collaborative networks in Europe. Developed together with many European colleagues, most notably professor Tom Huizinga from Leiden, these collaborations have led to productive networking both in European and international arthritis research in general. They have also contributed to the development of the new paradigm of arthritis prevention that is based on the improved understanding of how genes and environment gradually can cause the development of chronic inflammation in joints.8

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Wigzell, who has watched Dr. Klareskog’s growth as a scientist and collaborator, notes that his colleague’s earliest concerns with public health continue to inform his current approach to collaborations. One of Dr. Klareskog’s most successful ventures, he notes, is COMBINE Sweden, a consortium he initiated in June 2008, comprising academic medical researchers, clinicians, patient participants and industry representatives to enhance collaborations between stakeholders, with the motto, “Controlling Chronic Inflammatory Diseases with Combined Efforts.” The project also nurtures the careers of young rheumatologists, offering sponsorship and project management experience.

A Life in Science

Dr. Klareskog is well respected in the scientific community. “One of his attributes as a scientist is his great breadth,” says David S. Pisetsky, MD, PhD, professor of medicine and immunology at the Duke University Medical Center in Durham, N.C., chief of rheumatology at the Durham VA Medical Center and former editor of A&R (2000–2005) and of The Rheumatologist (2006–2011). Dr. Pisetsky, who considers Dr. Klareskog both a colleague and a good friend, notes that Dr. Klareskog’s other great strength has been the creation of collaborative networks. Both his scientific genius—he is an accomplished biochemist, immunologist, geneticist and epidemiologist—and his ability to collaborate, says Dr. Pisetsky, have contributed to his success.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“To move from one area of science to another requires extraordinary skill,” notes Dr. Pisetsky, “because you have to establish your credibility with each discipline. It does not happen every day that biochemists go into epidemiology. In addition, it is very difficult to create these networks and to keep them going.”

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsProfessional TopicsProfilesRheumatoid Arthritis Tagged with:CareerHenkelLeadershipRheumatoid arthritisrheumatologist

Related Articles

    Can Genetic Information Change the Clinical Care of Rheumatology Patients?

    February 15, 2017

    WASHINGTON, D.C.—Calling it an extremely challenging topic, Peter K. Gregersen, MD, professor and head, Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute, Manhasset, N.Y., said the current role of genetics in clinical practice is less about how to use genetic information to care for patients and more about how providers and patients…

    EUnited to Cure

    April 1, 2007

    AutoCure brings together researchers across Europe to combat RA

    Rheumatologists on the Move

    June 1, 2013

    Awards, appointments, and announcements in the world of rheumatology

    EULAR 2012: Rewards in Risk Factor Research

    September 5, 2012

    Investigations of infection and comorbidities offers hints to better understanding of rheumatoid arthritis.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences